market conditions

Claremont Creek Ventures’ portfolio company Gene Security Network in race for prenatal test

By Claremont Creek Alerts / December 15, 2011 / 0 Comments

September 9, 2011  source: originally published in the San Francisco Business Times Gene Security Network’s race to develop safer, more accurate prenatal test is all business for Matt Rabinowitz — and it’s personal. A relative of Rabinowitz, Gene Security Network’s CEO, took a blood test for the likelihood of Down’s syndrome in her unborn baby and […]

Read More

Entrepreneurs: The End Is Near. Refinance.

By John Steuart / September 28, 2011 / 0 Comments

September 28, 2011  source: Wall Street Journal All good things, unfortunately, come to an end. The last year or two have been spectacular for entrepreneurs. Investor enthusiasm has been intense, meaning that start-ups had the upper hand and could get financing at extraordinarily generous terms. But I’m afraid that the curtain is about to fall. […]

Read More

Goldhaber claims there’s still plenty of investor enthusiasm for companies that are installing or financing solar projects

By Claremont Creek Alerts / September 25, 2011 / 0 Comments

September  23, 2011  source: Forbes What the Solyndra Bankruptcy Means for Cleantech Investors by Jennifer Kho. Forbes Contributor As executives of defunct solar-panel manufacturer Solyndra keep mum in Washington, Silicon Valley and Wall Street are discussing what the bankruptcy – and the federal investigation – could mean for investors. “It has an impact; it’s such a […]

Read More

IPOs look dicey, but private equity may pick up some of the slack

By Claremont Creek Alerts / September 15, 2011 / 0 Comments

September 15, 2011  source: Xconomy For a while, I was optimistic that 2011 would be a good year for venture capital-backed IPOs, and it wasn’t just wishful thinking. There were 72 VC-backed IPOs last year—six times as many as in 2009. The year ended with a bang and 2011 got off to a good start. […]

Read More

Molecular Diagnostics World Congress, Venture Capitalists’ Best Practices on Commercializing Innovation

By John Steuart / July 22, 2011 / 0 Comments

I will be moderating a panel, Venture Capitalists’ Best Practices on Commercializing Innovation at the Molecular Diagnostics World Congress on September 29, 2011 at the South San Francisco Conference Center. Here’s the panel topic summary, hope to see you there. Successful venture capital investing in molecular diagnostics requires proper commercialization of innovation. But how does this innovation get […]

Read More

What Does It Take to Swing the IPO Window Open for Biotechs? – Suggestions include selling at a discount at a time when there is a rising investor fan-base for social media.

By Claremont Creek Alerts / June 22, 2011 / 0 Comments

June 22, 2011  source: Genetic Engineering and Biotechnology News On June 10, a day after withdrawing an $86 million IPO filed in November 2010, Ambit Biosciences reported securing $30 million in Series D-2 equity financing. “The terms currently obtainable in the public marketplace are not sufficiently attractive to the registrant to warrant proceeding with the […]

Read More

Meet our team

Claremont Creek Ventures was founded in 2005 by Nat Goldhaber, John Steuart and Randy Hawks to pursue early stage investing in exceptional technology startups.

Nat_Boldhaber7718 -1200px

NAT GOLDHABER

Nat Goldhaber is a co-founder of Claremont Creek Ventures. 

Brad_Webb8124 1200px crop

BRAD WEBB

Brad is focused on the role of genomics and biomarker data analytics in driving the next generation of diagnostics and drug development.

Randy_Hawks7690 -1200px

RANDY HAWKS

Randy Hawks is a co-founder of Claremont Creek Ventures.

Post Categories

Archives